What question did this study set out to answer?

To evaluate the efficacy of iptacopan in slowing kidney function decline in IgA nephropathy patients.

April 1, 2026

Iptacopan in IgA Nephropathy — Final 24-Month Data

Key Points

To evaluate the efficacy of iptacopan in slowing kidney function decline in IgA nephropathy patients.
Clinical trial comparing iptacopan therapy with placebo.
Assessment of kidney function over 24 months.
Iptacopan therapy resulted in a significantly slower decline in kidney function compared to placebo.

Abstract

Iptacopan therapy led to a significantly slower decline in kidney function than placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).

Bookmark

Cite This Study

Barratt et al. (Sat,) studied this question.

synapsesocial.com/papers/69ccb55116edfba7beb875bc https://doi.org/https://doi.org/10.1056/nejmoa2600743

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria2024 · 141 citations
2Simple and Effective Confidence Intervals for Proportions and Differences of Proportions Result from Adding Two Successes and Two Failures2000 · 508 citations
3General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale2018 · 177 citations
4Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score2012 · 149 citations
5Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients2021 · 47 citations

Bookmark